Drug intelligence / Profile preview

SR-T100

Development stage
Phase 3
Lead developer
G&E Herbal Biotechnology
Modality
Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

SR-T100 is a topical pharmaceutical gel developed for the treatment of actinic keratosis and other skin lesions. Its active component is solamargine, a steroidal glycoalkaloid extracted from Solanum undatum (also referred to as Solanum incanum in some studies). The drug acts primarily by inducing apoptosis and causing G0/G1 cell cycle arrest in abnormal or malignant skin cells. Preclinical and clinical studies have demonstrated its efficacy against actinic keratosis, Bowen's disease (cutaneous squamous cell carcinoma in situ), common warts (verruca vulgaris), genital warts, and even melanoma cells. Mechanistically, solamargine down-regulates HER2/neu receptors and aldehyde dehydrogenase 1—markers associated with cancer stem-like cells—and promotes DNA damage leading to cancer cell death. SR-T100 has shown favorable safety profiles compared to other topical agents such as 5-fluorouracil, imiquimod, diclofenac, and ingenol mebutate[1][2][3][6][7].

Brand names
SR-T100 GelSR-T-100 GelSR-T 100 Gel
Other names
Solanum undatum extractsolamargine topical gel
02

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)FOXM1 (Forkhead box protein M1)NOTCH (Neurogenic locus notch homolog protein 3)BCL-2 (BCL-2 family)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SR-T100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-T100.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call